Nasdaq Blte News Today

SAN DIEGO, March 11, 2024 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE), a clinical-stage biopharmaceutical drug development company focused on...

Shares of Belite Bio, Inc (NASDAQ:BLTE – Get Free Report) have been given an average recommendation of “Buy” by the seven analysts that are covering the company, Marketbeat reports. Seven research analysts have rated the stock with a buy recommendation. The average 12-month price target among analysts that have covered the stock in the last […]

Belite Bio, Inc (NASDAQ:BLTE – Get Free Report) has received a consensus recommendation of “Buy” from the seven research firms that are currently covering the firm, MarketBeat reports. Seven equities research analysts have rated the stock with a buy recommendation. The average twelve-month target price among analysts that have updated their coverage on the stock […]

Research analysts at Maxim Group initiated coverage on shares of Belite Bio (NASDAQ:BLTE – Get Free Report) in a report issued on Thursday, Briefing.com reports. The firm set a “buy” rating and a $60.00 price target on the stock. Maxim Group’s price target indicates a potential upside of 35.76% from the stock’s current price. BLTE […]

Belite Bio, Inc (NASDAQ:BLTE – Get Free Report) has been assigned a consensus rating of “Buy” from the six research firms that are presently covering the firm, Marketbeat Ratings reports. Six equities research analysts have rated the stock with a buy rating. The average 12 month price objective among analysts that have issued a report […]

Belite Bio, Inc (NASDAQ:BLTE – Get Free Report) was the target of a large decline in short interest during the month of November. As of November 15th, there was short interest totalling 87,500 shares, a decline of 9.7% from the October 31st total of 96,900 shares. Based on an average daily volume of 117,300 shares, […]

Belite Bio, Inc (NASDAQ:BLTE – Get Free Report) was the recipient of a large decline in short interest in the month of November. As of November 15th, there was short interest totalling 87,500 shares, a decline of 9.7% from the October 31st total of 96,900 shares. Based on an average trading volume of 117,300 shares, […]

HC Wainwright reiterated their buy rating on shares of Belite Bio (NASDAQ:BLTE – Free Report) in a research note issued to investors on Wednesday morning, Benzinga reports. HC Wainwright currently has a $59.00 price target on the stock. HC Wainwright also issued estimates for Belite Bio’s Q4 2023 earnings at ($0.30) EPS, FY2023 earnings at […]

Belite Bio, Inc (NASDAQ:BLTE – Get Free Report) has received a consensus rating of “Buy” from the six brokerages that are currently covering the company, MarketBeat.com reports. Six analysts have rated the stock with a buy rating. The average 1 year price objective among brokerages that have updated their coverage on the stock in the […]

Belite Bio (NASDAQ:BLTE – Get Free Report) issued its earnings results on Monday. The company reported ($0.40) EPS for the quarter, missing analysts’ consensus estimates of ($0.31) by ($0.09), MarketWatch Earnings reports. Belite Bio Stock Down 1.3 % NASDAQ BLTE traded down $0.51 during trading hours on Wednesday, hitting $37.37. 36,637 shares of the company’s […]